CDR609 Announced as New T-Cell Engager Clinical Candidate Targeting LGR5 in Solid Tumors July 1, 2025
New arm (Cohort 4) initiated in SCOPE Ph 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+ June 26, 2025
IDeate-Prostate01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic CRPC June 24, 2025
Recruitment for [212Pb]VMT-α-NET Commenced in the Third Dose Escalation Cohort of Ongoing Ph 1/2a Clinical Trial June 24, 2025
First Patient Completes DLT Observation Period with No Reported DLTs in Ph 1 Trial of CER-1236 June 24, 2025
First patient dosed in DESTINY-Endometrial01 Ph 3 Trial of ENHERTU® Initiated as 1L Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer June 17, 2025
First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC) June 17, 2025
FDA Removes Partial Clinical Hold from Ph 3 Trial of IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma June 11, 2025
First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Dose escalation completed in IAM1363-01 Ph 1/1b trial of IAM1363 in patients with HER2-altered cancers & brain mets / HER2 TKD mutation / HER2-amplified NSCLC June 10, 2025
Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors June 10, 2025
First Patient Enrolled in New Ph 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer June 3, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated May 27, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
